12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Esbriet regulatory update

Germany's Federal Joint Committee (G-BA) issued a more favorable assessment of idiopathic pulmonary fibrosis (IPF) drug Esbriet pirfenidone from InterMune than did the Institute for Quality and Efficiency in Health Care (IQWiG). In a final benefit assessment, G-BA said Esbriet provides an additional benefit over best supportive care, but the benefit is not quantifiable. In December, IQWiG said in...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >